findmyKOL
Clinical trialNCT07274059RecruitingEarly phase 1Interventional

Allogeneic UCB-derived CAR-T for SLE

SponsorChengdu Ucello Biotechnology Co., Ltd.Enrollment48SLE - Systemic Lupus Erythematosus
View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

2 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

China
  • Yancheng Third People'S Hospital

    Yancheng, Jiangsu, China

    Dongmei Jiang, M.D.
    Recruiting
  • the General Hospital of Western Theater Command

    Chengdu, Sichuan, China

    Tao Wang, M.D.
    Not, yet, recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
26 Mar 2025
Primary completion
31 Dec 2035
Completion
31 Dec 2037
Last update posted
10 Dec 2025
Registered enrollment
48
Registry id
NCT07274059

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.